Juvenile rheumatoid arthritis (JRA), also known as juvenile idiopathic arthritis (JIA), includes the most common chronic autoimmune arthropathies of childhood. These two nomenclatures for classification include components representing the major subclasses of disease. The chromosomal regions and the genes involved in these complex genetic traits are being elucidated, with findings often specific for a particular disease subtype. With the advent of new SNP technologies, progress is being made at an ever-increasing pace. This review discusses the difficulties of deciphering the genetic components in complex disorders, while demonstrating the similarities that JRA shares with other autoimmune disorders. Particular emphasis has been placed on positive findings either for candidate genes that have been replicated independently in JRA/JIA, or findings in JRA for which consistent results have been reported in other forms of autoimmunity.
Introduction
Juvenile rheumatoid arthritis (JRA) comprises the most common chronic autoimmune arthropathies of childhood. Strong evidence is emerging to suggest that the disease likely involves multiple susceptibility genes, a feature common to many autoimmune disorders. Investigations of the basis for this genetic susceptibility have identified genes in common with other autoimmune disorders as well as variants specific to JRA. Thus, the combination of both general autoimmune genes and JRA-specific genes contributes to the clinical presentation of the JRA phenotypes. While the etiology of disease is not fully understood, there is evidence of inflammatory cells trafficking to the synovium, causing local inflammation and progressive joint damage. 1 Features of JRA also include inflammation with T-cell and macrophage infiltration, Th1 cytokine predominance in tissues, evidence of T-cell clonality, and by inference, antigen presentation. Some autoantibodies are present in the peripheral blood. Associations and linkage to the human leukocyte antigen (HLA) region have been well documented. The HLA alleles involved in JRA are largely different from adult RA and from any other autoimmune disease, at least in Caucasian populations. Another feature of JRA consistent with autoimmunity is the female preponderance.
The disease, also now known as juvenile idiopathic arthritis (JIA), and in older European literature as juvenile chronic arthritis (JCA), affects approximately one in 1000 children in North American and European populations. Current treatment focuses on curbing inflammation through anti-inflammatory and immunosuppressive strategies, including methotrexate and antitumor necrosis factor (TNF) therapies. As the complex genetic nature of this disease is dissected, a better understanding emerges both of the pathogenic mechanisms in common with global autoimmunity, as well as those mechanisms that are JRA-specific. This paper then focuses on evidence for general autoimmune susceptibility genes and their role in JRA, with emphasis on the status of data replication.
Issues of phenotype definition
Genetic studies in JRA, as with other autoimmune diseases, are difficult because of the complex nature of disease pathogenesis and the various presenting phenotypes that are likely to involve different susceptibility genes. Moreover, the classification of pediatric rheumatic disease is confounded by phenotype variation between ethnicities, as well as the heterogeneity of the disease and the multiple classifications in use clinically and in the literature. Three different classification systems have been used (or are in use) to describe the subsets of the disease ( Table 1) .
The American College of Rheumatology (ACR) supports the nomenclature JRA (including pauciarticular, polyarticular, and systemic onset). 2 Although no longer in use, the European League Against Rheumatism (EULAR) used the nomenclature JCA, which included not only pauciarticular, polyarticular, and the systemic forms, but also juvenile psoriatic arthritis, juvenile ankylosing spondylitis, and irritable bowl disease. 3 Finally, in an attempt to replace the existing nomenclature, which lacked the classification power needed for all forms of juvenile arthritis, the International League of Associations for Rheumatology (ILAR) sponsored the nomenclature JIA, encompassing all forms of juvenile arthritis of unknown etiology. [4] [5] [6] Worldwide, the pediatric rheumatic community has accepted JIA as a replacement for JCA, except in the United States, where JRA is the common usage. This complexity in nomenclature is confounded by the lack of specific diagnostic tests for JRA, making clinical observation critical to phenotype definition and subtype classification.
JRA and autoimmune traits
Despite the issues discussed above, progress has been made in identifying genetic associations in JRA (Table 2) . Each novel association continues to add weight to the concept that JRA is a complex genetic trait. 42 Recent data reviewed herein suggest that some genes contribute to an individual's susceptibility to autoimmunity (including JRA), while others, such as human leukocyte antigen (HLA) polymorphisms, predispose them to a specific autoimmune disease or phenotype. Even with JRA, these HLA polymorphisms are thought to contribute to susceptibility in a subtype-specific manner (reviewed elsewhere 43 ). The familial history of JRA is almost entirely limited to affected sib pairs, except for a small number of multigenerational affected families. This limited availability of extended pedigrees represents a marked difference from RA. It is noteworthy that the affected sib pairs have a considerable concordance for clinical phenotypes 44 and for HLA haplotypes. 45 Also reported in affected sib pairs is an absence of familial aggregation for the year of JRA onset, which is in contrast to a rather significant aggregation for age at onset. 44 In addition, of the 14 sets of affected twins identified in the affected sib pair registry, 11 were monozygous, all of whom were concordant for disease onset and course. This represents a reversal of the normal monozygous to dizygous twin ratio in North American populations, 46 and demonstrates the existence of a genetic component in JRA.
In contrast to the sparse familial history of JRA, a familial history of autoimmunity is readily observed in JRA families. 47 This family history was documented in 12.6% of first-and second-degree relatives of JRA probands, whereas only 4% of the control population was afflicted with an autoimmune disorder. 47 A considerable amount of literature supports the view that susceptibility genes, common pathologies and familial clustering exist in autoimmunity. 48 Yet, the systemic form of JRA lacks strong evidence of susceptibility genes and does not show a preponderance of familial autoimmunity. This subtype, with its febrile onset, has more in common with autoinflammatory disorders and has considerable evidence of NK cell and dendritic cell dysfunction.
Genetic polymorphisms associated with JRA
Macrophage migration inhibitory factor Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine expressed ubiquitously in leukocytes as well as nonimmune cells, and is a pivotal regulator of both innate and adaptive immune responses. MIF promotes macrophage intracellular killing, phagocytosis, and has been linked to the production of inflammatory cytokines such as IL-1, IL-6, and IL-8 among others. To date, four polymorphisms have been studied in the MIF gene: a G/C substitution in the promoter region at position À173, a tetranucleotide repeat (CATT) n beginning at position À794, a T/C substitution in intron 1, and a C/G substitution in intron 2. 10 Two of the these polymorphisms (À173G/C and CATT repeat) were separately found to alter the in vitro transcriptional activity of MIF. 8, 49 The evidence of a genetic role for MIF in inflammatory disease has been recently reviewed. 50 MIF has been associated with autoimmune disorders, including alopecia areata (OR ¼ 4.88 at À173G/C and 10.42 for CC) 7 and rheumatoid arthritis (RA, OR* ¼ 0.67 for À173G/C) 10 among others. However, recent negative MIF findings in a large study of RA patients (n ¼ 2370) emphasize the difficulties in arriving at a consensus. 21 Consistent with the association in human autoimmunity, MIF has been shown to play a critical role in murine models of experimental autoimmune encephalomyelitis (EAE), experimental autoimmune myocarditis (EAM), and type 1 insulin-dependent diabetes mellitus. Mechanistically, the polymorphic form of MIF may result in altered transcription-binding sites and lead to the upregulation of proinflammatory mediators. Such is the case for the À173 G/C polymorphism, which appears to result in an AP-4 transcription factor-binding site. 8 Furthermore, treatments inhibiting MIF in an induced in vivo T1D model led to decreased levels of proinflammatory mediators (TNFa and IFNg), increased antiinflammatory mediators (IL-10), and decreased T-cell clonal expansion (downregulation of IL-2R). 51 Anti-MIF treatment has also been shown to decrease cellular adhesion (via CD11b and ICAM-1) to specific target tissues in T1D, 51 glomerulonephritis, 52 EAE, and EAM. 53 While disease pathogenesis has been studied in murine models, more relevant (human) studies associated the À173G/C SNP in the MIF gene with JIA in two separate British cohorts of patients. 8 Additional work, focusing on clinical features of functional and prognostic relevance in systemic JIA patients, showed that the À173*C allele was related to a more severe disease course, including a greater number of arthritic joints and decreased response to medication. 54 More recently, in a German study, the (CATT) 5 allele, which is functionally related to MIF transcriptional activity, was found at higher allelic frequencies in JRA patients when compared to either healthy controls or RA patients. 10 In adult RA, circulating MIF levels in the sera have been directly related to the À173C and (CATT) 7 functional variants.
Furthermore, the levels of MIF have been correlated with radiologic joint damage. 55 Taken together, these studies implicate a functional role for MIF in the pathogenesis of arthritis, both adult and pediatric, as well as other forms of autoimmunity.
Cytotoxic T-lymphocyte antigen 4
Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a surface molecule present on T-cells that plays an immunologically important role in downregulating the immune response. Currently, the mechanism of action of CTLA-4 is unknown, although multiple theories exist. Downregulation of the immune response may result from competitive binding for CD80/86, which prevents costimulation of the T-cell through CD28, or inhibiting T-cell signaling by limiting the amount of available T-cell receptor (TCR) z. Recently, it has been suggested that two isoforms of CTLA-4, soluble (sCTLA-4) and full length are needed for proper signal inhibition and that the serum levels of sCTLA-4 may be critical to downregulating T-cell activity. Conversely, it has been postulated that CTLA-4 may in fact activate certain T-cells known as T regulatory cells (CD4 þ CD25 þ ). 56 Due to the central role of CTLA-4 in immune function, its [19] [20] [21] and systemic lupus erythematosus. 22 However, this polymorphism was recently excluded as being the causal variant in Graves' disease, autoimmune hypothyroidism, and type I diabetes mellitus. Investigations of the þ 49A/G polymorphism in JRA cohorts have been negative. These studies have included two USbased cohorts and a German cohort. The first US cohort included 340 probands in a TDT analysis, and the second employed a case-control design and included 120 probands and 180 unrelated ethnicity-matched controls. 57 The German cohort included 197 JRA patients and 362 controls. 10 In addition to studying the þ 49G/T polymorphism, the German investigators also extended their studies to include a À318C/T promoter region SNP. Investigations of this SNP in autoimmune disease have been largely negative, 58 with only limited positive associations reported. 59 For JRA, significant findings were reported in the German cohort (P ¼ 0.001, OR* ¼ 2.05), 10 but were not replicated in the US cohorts. 57 These contradictory findings illustrate the difficulties involved in the candidate gene approach leaving the potential role of CTLA-4 in JRA unresolved. Furthermore, the limited size of available cohorts presents power issues for most studies and makes replication difficult.
Protein tyrosine phosphatase N22 PTPN22, also known as Lyp, is an intracellular tyrosine phosphatase found in T-cells, as well as other hematopoeitic cells, and is believed to play a role in lowering the threshold for TCR signaling. The murine homolog of PTPN22 is PEP (PEST domain-enriched tyrosine phosphatase), which dephosphorylates critical TCR activation kinases such as Lck, Fyn, and ZAP-70. 60 Furthermore, PEP has been shown to bind to Csk, a negative regulator of Lck. 61 While PEP knockout mice did not demonstrate an increase in autoimmunity, they did show signs of Tcell hyper-responsiveness. 62 A functional polymorphism has been identified in PTPN22 (1858C/T), resulting in an amino-acid change (R620W) in a potential Src-binding site. This change may decrease the functionality of the encoded phosphatase by disturbing the binding of PTPN22 to Csk. Moreover, Bottini et al. 63 reported that the PTPN22 R620W polymorphism was associated with T1D and since then associations have been reported in several separate studies in RA. 21, 64, 65 When the Multiple Autoimmune Disease Genetics Consortium cohort was analyzed for the same SNP, multiple autoimmune disorders, including RA, T1D, SLE, and Hashimoto's thyroiditis, were found to have an association, with the notable exception of MS. 23, 66 Resequencing and haplotype analysis of this gene revealed 10 common haplotypes in Caucasian North Americans. Analysis of the association of RA with these haplotypes indicated that the association is not completely explained by R620W and there is at least one additional variant in the PTPN22 gene region that influences RA susceptibility. 67 Variants in PTPN22 have also been examined in pediatric arthritis. A study including a UK cohort (661 JIA patients) reported that the original SNP (1858C/T; rs2476601) was associated (P ¼ 0.0005, OR ¼ 1.53).
24 RA (886 patients), MS (379 patients), psoriasis (279 patients), or psoriatic arthritis (455 patients) cohorts were also investigated as part of this case-control study (595 controls). Of these other autoimmune diseases, the only significant association was with RA, consistent with the earlier findings discussed above (P ¼ 1.8 Â 10
À8
, OR ¼ 1.88). Interestingly, the 1858C/T polymorphism was not found to be associated with a Finnish cohort (230 JIA patients). However, when analyzing the cohort of homozygous variants the association was marginally significant (P ¼ 0.023). 25 As the author noted, the lack of a strong association may be reflective of population differences, or due to the relatively small cohort used. A successful replication of association for the 1858*T allele has recently been found in a North American JRA cohort. This family-based study included a group of 379 simplex and 146 multiplex families with JRA and replicated the original UK cohort association (OR* ¼ 1.28) (Thompson, unpublished data). Although this functional mutation appears to be important in JRA and other autoimmune diseases (mentioned above), the lack of association in MS suggests that it is not critical to all autoimmune disorders. This is consistent with the suggested immunological mechanism of PTPN22 variants -lower TCR signaling threshold -and conforms to the pattern of the influx of T-cells found in synovial fluid isolated from JRA children. These populations of clonally expanded T-cells have been reported in JRA in addition to other forms of arthritis. 68 Together, these findings support a role for PTPN22 in JRA pathogenesis and add to the notion that multiple susceptibility genes lead to different autoimmune pathologies.
Tumor necrosis factor alpha TNFa is one of the primary mediators of acute inflammation. TNFa is a cytokine secreted principally by macrophages and monocytes. Once in the synovium, TNFa has pleiotropic effects, helping activate lymphocytes, osteoclasts and fibroblasts among other inflammatory cells. Specifically, TNFa stimulates synoviocytes, leading to synovial inflammation and pannus formation. 69 Furthermore, TNFa and its receptors are expressed in the synovium of JRA patients. 70 The TNFa locus is within the MHC region of chromosome 6 (6p21.3), between the classical HLA class I and II genes. TNFa plays a role in the pathogenesis of autoimmunity, as evidenced by the multiple associations found between this locus and different autoimmune disorders. In diseases such as RA and Crohn's disease, excess TNFa appears to contribute to disease pathogenesis. TNFa has been shown to be a critical mediator of autoimmunity in RA, inhibiting the generation of plasmacytoid dendritic cells, which secrete interferon alpha and beta (IFNa/b). 71 In these instances, anti-TNFa treatments have been very successful. Similarly, antiTNFa treatments have worked well in JRA. 72 However, in such diseases as MS and SLE, a drop in circulating TNFa resulted in more severe symptoms. 73 The association of TNFa gene polymorphisms with JRA has long been established, with significant increased disease risks reported over the past decade in multiple studies. 27, 28, [74] [75] [76] [77] [78] For example, in a Japanese cohort of 111 affected JRA patients, Date et al. 27 found three susceptibility loci (À1031C, À863A, and À857T) within the TNFa locus. When the cohort was stratified by disease subtype, all three loci were found to confer increased risk of disease in systemic patients. Combined with the HLA DRB1*0405 allele, the TNFa À857T allele showed an increase in susceptibility (OR ¼ 3.84, Po0.001). While the genetic studies have yet to replicate subtype findings, the substantial impact of anti-TNFa therapy, coupled with the multiple associations, suggest that the polymorphic variants of TNFa and its receptors are likely to have a role in the pathogenesis of JRA and susceptibility to autoimmunity. SLC11A1 SLC11A1, formerly known as NRAMP1, encodes a macrophage-specific divalent transition metal (iron and manganese) transporter involved in iron metabolism and host resistance to certain pathogens, including leshmaniasis and tuberculosis. Pathogen resistance involves sequestration of Fe 2 þ and Mn 2 þ , cofactors of both prokaryotic and eukaryotic catalases and superoxide dismutases, not only to protect the macrophage against its own generation of reactive oxygen species, but also to deny the cations to the pathogen for synthesis of its protective enzymes. SLC11A1 has been hypothesized to regulate a balance between protection from infectious disease versus susceptibility to autoimmunity. 79, 80 SLC11A1 polymorphisms have been associated with autoimmune diseases; for instance, promoter region allele 3 has been associated with RA 33 and with diabetes in patients with first-or second-degree relatives with RA. 34 In addition, two individual haplotypes were associated with Crohn's disease, 30 giving support that SLC11A1 may be one of the many general autoimmune susceptibility genes.
Consistent with the findings for other autoimmune diseases, an association has been reported in a cohort of Latvian and Russian JRA patients when SLC11A1 (NRAMP1) and D2S1471 were typed (SLC11A1 allele 3, OR ¼ 2.26). 31 Allele 3 represents a functional promoter polymorphism, which is possibly an enhancer element. In vitro, using reporter constructs for the gene, allele 3 has been shown to drive increased expression of SLC11A1.
81 Examining findings at a subtype level, both pauciarticular and polyarticular onset patients considered separately showed increased risk (OR ¼ 2.31, and 2.19 respectively). Conversely, allele 2 was found to confer protection for JRA (without stratification) as well as for the pauciarticular and polyarticular subtypes (OR ¼ 0.44, 0.43, and 0.46). Natural selection appears to balance, between these two alleles, susceptibility to infectious disease with susceptibility to autoimmunity.
Additional support for the existence of a susceptibility locus at or near SLC11A1 has been provided by a study of Finnish families classified by JIA criteria. While the initial findings were not replicated for the SLC11A1 allele 3, the study did associate the region with susceptibility to JIA. Both microsatellites from the previous study were typed, in addition to three SNPs and 1 insertion/deletion that lie between the two microsatellites. One six-marker haplotype showed impressive odds ratios in all JIA, as well as in persistent oligoarticular and rheumatoid factor-negative polyarticular patients (OR ¼ 4.0, 3.5, and 4.1, respectively). 32 However, significance was also shown in haplotypes not containing the SLC11A1 allele 3, suggesting that loci may not be directly related to JIA, even though the region surrounding SLC11A1 is important to disease susceptibility. 32 Interferon regulatory factor-1 Interferon regulatory factor-1 (IRF-1) is a transcription factor with antiviral, proinflammatory, and tumor suppressor properties. The gene is located on chromosome 5q31 within a cytokine gene cluster. IRF-1 regulates IFNgmediated signaling important in the development and function of NK cells and cytotoxic T-cells (CD8 þ ). In addition, it binds to the upstream cis elements of both IFNa and IFNb, thereby regulating multiple IFN-inducible genes. These regulated genes include MHC class I and II genes, IL-6, inducible nitric oxide synthetase, as well as the adhesion molecules ICAM1 and VCAM1. IRF-1 has been shown to induce CD4 þ Th1 polarization; similarly, IRF-1 knockout mice have demonstrated the molecule's importance in T-cell selection. 35, 82, 83 IRF-1 has been implicated in the pathophysiology of the autoimmune manifestations sometimes seen in human myelodysplasia. Patients with autoimmune manifestations and healthy controls had much higher levels of IRF-1 mRNA than patients lacking these manifestations. 84 Owing to the central role for IRF-1 as a transcription factor in immune regulation and the potential relationship to autoimmunity, Donn et al. 35 included this gene in a JIA association study considering several candidate cytokine genes. A novel SNP (1688A/G), located in the 3 0 UTR IRF-1, was identified by sequence alignment. Employing a case-control design (351 UK Caucasian JIA patients and 246 unrelated healthy UK Caucasian individuals), this study reported an apparent reduction in homozygosity for the A allele (P ¼ 0.002). There was no evidence of difference in distribution of IRF-1 genotypes when JIA subgroups were considered separately. The functional importance of this polymorphism has not yet been reported. It is attractive to propose a scenario in which this reduction of the AA genotype in JIA patients is related to reduced quantities of IRF-1, resulting in suboptimal induction of IFNa and IFNg. Thus, a viral infection might not be properly controlled, leading to subsequent development of autoimmune pathology. 35 To date, replication of this finding in JIA/ JRA has not been reported, while investigations of association for IRF-1 to other autoimmune diseases have, to our knowledge, been negative thus far. 85, 86 Replication of the finding in another JIA/JRA cohort would help cement the role of IRF-1 in disease-specific pathology.
Interleukin-1 alpha
Interleukin-1 alpha (IL-1a), found on chromosome 2, is a strong proinflammatory cytokine that has catabolic effects on both cartilage and bone. It is made in multiple cell types, including macrophages, keratinocytes, activated B-cells, and fibroblasts, and may possibly have a central role in autoimmunity. Similarly, a study in RA has shown that certain IL-1a alleles may contribute to bone erosion, although linkage was not demonstrated by nonparametric analysis methods. 37 However, in a pediatric population of Norwegian JRA patients, an IL-1a promoter region polymorphism, À889C/T, was associated with early-onset pauciarticular patients (OR ¼ 2.1) . 36 Yet, other investigations using two additional cohorts in Britain were not able to replicate these findings. 35, 87 It may be possible that the failure of replication has illuminated a false positive, or that this association is specific to the geographically (and genetically) distinct, Norwegian cohort. In either case, it is noteworthy to highlight the publication of the negative findings. To our knowledge, a positive association has not been reported in any other JRA cohort.
Interleukin-6
Interleukin-6 is a pleiotropic cytokine expressed by multiple leukocytes, including B-cells, T-cells, and synoviocytes. It is believed to be involved in adaptive immunity, mediating B-cell growth, hematopoiesis, and acute-phase responses. Additionally, the IL-6 À174G/C SNP in the promoter region has been found to be functionally important, leading to increased levels of inflammation with the G allele. 88 Moreover, IL-6 has been associated with autoimmune disorders such as T1D 40 and SLE 41 , whereas the association with JRA has only been defined for those patients with systemic onset. By the same token, systemic onset patients alone have been found to have elevated levels of IL-6 in their sera and synovial fluid. 89 This elevation also coincides with disease-associated fever. 76 The first association in juvenile arthritis employed a case-control design in a cohort of British patients classified using the JCA terminology. When the entire cohort was analyzed (92 systemic JCA patients), a Pvalue of 0.03 was obtained. However, after stratifying by age of onset, a subset of systemic patients (p5 years of age at onset) was found to have a stronger association with the À174G/C allele (P ¼ 0.01). 38 To confirm these findings, a multinational family-based cohort was assembled. In this case, use of the transmission disequilibrium test (TDT) provided an alternate analysis method, which was not subject to population stratification. Briefly, systemic onset JRA/JIA patients and parents from the UK, US, and France were genotyped for the À174G nucleotide variant of the IL-6 gene promoter. This family-based study found a significant over transmission of the À174G allele to JRA offspring (P ¼ 0.041). When this multinational cohort was stratified by age of onset, a P-value of 0.007 was achieved for patients who developed disease after 5 years of age. 39 Age-related windows of susceptibility have been reported for other genetic polymorphisms in JRA 90 , consistent with this IL-6 finding. Thus, genetic heterogeneity may be present even within current disease subtype classification.
The future of genetic research in JRA As advances in competing technologies provide a larger number of available SNPs at lower and lower costs, the potential for genome-wide association studies will continue to increase. At this time, the only reported genome-wide genetic study in JRA/JIA was completed in 121 multiplex families using 384 microsatellites. The genome-wide scan identified multiple susceptibility regions in spite of the modest numbers of affected sib pairs available and the phenotype complexity. All regions with a LOD41.0 were reported; 17 areas of interest (LOD41.5) in all were described after stratification by JRA criteria of disease onset, course, and age. These stratified populations likely represent molecularly different diseases that share the common phenotype of arthritis. 91 However, only six regions were reported for JRA (without stratification). Independent replication of these findings is important for all regions and dependent on the availability of suitable cohorts. As illustrated in Figure 1 , some of these regions overlapped with chromosome regions common to other forms of autoimmunity, 92-100 while other regions were unique to JRA. The idea of comparing multiple genome-wide scans for general autoimmune susceptibility loci is not new; Becker et al. 101 proposed the idea 8 years ago in a metaanalysis of 23 genome-wide scans. This study reviewed five human autoimmune diseases and seven experimental animal models. The study reported 18 regions of linkage overlapping between two or more forms of autoimmunity. However, the shared chromosome regions identified in the genome-wide scans do not include the candidate genes identified thus far ( Table 2 ). The following question can then be raised: are both approaches -candidate gene versus discovery basedvalid if they do not provide the same results? The answer is likely to be yes; both approaches have their advantages and disadvantages, and both have been and will be helpful in identifying susceptibility genes in JRA. Evidence of overlapping associations between multiple autoimmune diseases have led to the notion of common pathologies. 102 These pathologies, and the elucidation of the genes causing them, are critical to understanding the complex factors leading to autoimmunity, including JRA. No matter the approach taken, it is clear that the search for autoimmune and JRA susceptibility genes must not be limited to the MHC.
Conclusion
Growing bodies of data, with respect to JRA/JIA genetic susceptibility, are consistent with a view that the development of an autoimmune childhood arthropathy results, in part, from the merging of two sets of susceptibility genes. The first set, specific susceptibility alleles, of which the MHC and the classical HLA polymorphisms provide the best documented source to date, are likely to contribute to subtype-specific pathologies, as evidenced by the unique chromosome regions identified in the genome-wide scan. 91 Based upon their function, the second set of susceptibility genes must be, by their very nature, general to autoimmune disorders. As described in this review, they are characterized by a genome-wide distribution, relatively low odds ratios, and are variably present in other forms of autoimmunity. The combination of several of these susceptibility genes culminates in the loss of tolerance to self and a resulting autoimmune or autoinflammatory pathology.
Replication studies are needed in order to validate the existing candidate gene results, as well as new findings in studies such as the genome-wide scan. These replication studies are essential to eliminate the falsepositive results inherent to large-scale association and linkage studies. Only by eliminating the potential false positives can we hope to find the underlying cause of disease. Identifying these regions and subsequent genes involved in JRA will take us one step closer to understanding the mechanisms of autoimmunity and provide better targets for treatment to these debilitating disorders.
